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Our report describes a case of 57-year-old man with manifest heart failure on the basis of
cardiac amyloidosis, which was detected by endomyocardial biopsy. Due to the heart
failure, the patient was unable to undergo myeloablative therapy. We changed our previous
decision for conservative therapy of heart failure and the patient underwent heart
transplantation. Autologous stem cell transplantation was performed 6 months later.
After the successful stem cell transplantation, the serum free light chain lambda levels
promptly decreased. One year later, their levels started again to increase. Chemotherapy
was therefore initiated. The patient has now completed the seventh cycle of chemotherapy
in good condition. The graft function is normal and the latest endomyocardial biopsy
revealed no amyloid.
& 2012 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
.1. Introduction
Amyloidosis is a heterogeneous group of diseases associated
with the extracellular deposition of protein fibers of different
composition called amyloid [1]. Amyloid fibrils form thech Society of Cardiology.
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c o r e t v a s a 5 5 ( 2 0 1 3 ) e 4 6 8 – e 4 7 3 e46910 cases per million persons [2]. Diagnosis of cardiac amyloi-
dosis is based on clinical symptoms and investigative meth-
ods, such as electrocardiogram, echocardiography, magnetic
resonance and laboratory screening. The gold standard of
diagnosis is the histological identification of amyloid in an
endomyocardial biopsy.2. Case report
Our report describes a case of 57-year-old man with a history
of diaphragmatic myocardial infarction, treated by direct
percutaneous coronary intervention with stent implantation.
At that time (May 2009), the left ventricle ejection fraction
(LVEF) was 40%. In February 2010, the patient was hospita-
lized for cardiac decompensation. LVEF was found to have
further decreased to 30%. Echocardiographic examination
performed at our institution in April 2010 showed a con-
centric hypertrophy of the non-dilated left ventricle (Fig. 1)
with systolic dysfunction; LVEF was 30%. A ‘‘granular glass’’
picture was observed in the interventricular septum (Fig. 2).Fig. 1 – Transthoracic echocardiography (parasternal long-
axis view)—a concentric hypertrophy of the left ventricle
(interventricular septum—17 mm, posterior wall—17 mm).
Fig. 2 – Transthoracic echocardiography (apical 4-chamber
view )—a ‘‘granular glass’’ picture in the interventricular
septum.Both atria and the right ventricle were also dilated. Low
voltage of QRS complex in limb leads was present in the
initial electrocardiogram (Fig. 3). Due to these findings,
cardiac amyloidosis was suspected. An endomyocardial
biopsy and laboratory screening were performed. The biopsy
showed the presence of amyloid substances in the myocar-
dium. High levels of free light chain lambda were present in
serum. During this hospitalization, the patient was resusci-
tated for circulatory arrest (suspected ventricular fibrillation)
and a defibrillator was implanted as a secondary prevention
of sudden cardiac death. Because of the heart failure, the
patient was unable to undergo the myeloablative therapy.
The hemato-oncologist indicated lower-dose dexamethasone
and cyclophosphamide therapy instead. Repeated cardiac
decompensations occurred during this therapy. For this
reason, the previous cardiological decision was changed
and the patient was transferred to our department for
consideration of heart transplantation with subsequent auto-
logous stem cell transplantation (ASCT). No disability of the
other organs, except for macroglossia, was proved. The liver
biopsy was negative for the presence of amyloid. A renal
biopsy was not indicated because of only mild renal insuffi-
ciency (level of serum urea was 15.5 mmol/l and creatinine
115 umol/l) without proteinuria, glomerular filtration was
1.44 ml/s. A rectal biopsy was not performed because the
diagnosis was established and there were no clinical signs of
gastrointestinal involvement. The patient was indicated for
heart transplantation and was put on an urgent waiting list.
He waited 38 days. The heart transplantation was performed
on August 2, 2010. Distinct grade amyloidosis was proved in
the explanted heart: multifocal deposits of amyloid in the
myocardium, valves and coronary arteries (Figs. 4 and 5).
The postoperative course was without serious complications,
the biopsies were favorable and the patient was dismissed on
the 30th post-transplant day. The patient had a standard
prophylaxis of infectious complications for 6 months, which
consisted of sulfonamide antibiotic (trimethoprim/sulfa-
methoxazole) and a local antifungal therapy. An amyloid in
the transplanted heart was first detected during a scheduled
endomyocardial biopsy in January 2011 (6 months after
transplantation) without echocardiographic abnormalities.
At that time ASCTwas already planned. This procedure was
reviewed with the hemato-oncologist and the patient was
hospitalized in the hemato-oncological department one
month later. The peripheral stem cells were stimulated by
growth factors and subsequently separated. In March 2011,
high-dose myeloablative chemotherapy (HDM) was per-
formed by melphalan at a reduced dose of 100 mg/m2
followed by ASCT. Mycophenolate mofetil was replaced with
an increase in prednisolone dosage during stem cell con-
sumption and the duration of HDM–ASCTuntil hematological
engraftment. The patient was during this transplantation
covered with anti-infective prophylaxis by administering of
parenteral fluoroquinoline antibiotic (ciprofloxacin) and tria-
zole antifungal drug (fluconazole). After his discharge sulfo-
namide antibiotic (trimethoprim/sulfamethoxazole) was
administered for long-term prophylaxis. After successful
ASCT, the serum free light chain lambda levels promptly
decreased from the highest value of 335 mg/l to 46 mg/l. This
favorable state lasted about one year. After that, the free light
Fig. 3 – Electrocardiogram—low voltage of QRS complex in limb leads.
Fig. 4 – Histological sample of explanted heart—multiplicities
districts of interstitial deposits of amyloid (Congo Red staining).
(For interpretation of the references to color in this figure
legend, the reader is referred to the web version of this article.)
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 4 6 8 – e 4 7 3e470chain lambda levels increased to 105 mg/l. During a regular
hemato-oncological check-up, the decision was made for 6–8
chemotherapy cycles with a bortezomib, doxorubicin and
dexamethasone (BDD) regime. The first cycle was completed
in February 2012. The second cycle of chemotherapy was
planned a month later, but was postponed as the patient
was taken to our department for swelling of the legs and
worsening of dyspnea. The initial echocardiographic exam-
ination did not show a worsening of systolic function of the
left ventricle; LVEF was 60%, but there was diastolic left
ventricle dysfunction and a dilatation of the right ventricle
with a mild dysfunction. There were no signs of pulmonary
hypertension. The cyclosporine A level in serum was within
therapeutic ranges (253 ug/l). The immunosuppression ther-
apy consists of cyclosporine, mycophenolate mofetil and
prednisone at that time. We performed an acute endomyo-
cardial biopsy. A cellular rejection grade IB according toBanff’s clasification was captured, which was treated with 3
doses of methylprednisolone. The control biopsy was grade 0,
without the presence of amyloid. Swelling of the legs
resolved and the patient was dismissed. According to the
latest laboratory checks, the free light chain lambda levels
decreased from 105 mg/l before the beginning of adjuvant
chemotherapy to the current value, which is 15.6 mg/l
(Table 1, Graph 1). The patient has now completed the
seventh series of chemotherapy. The latest free light chain
lambda levels are within normal ranges. The patient is in
oncological remission. Subjectively he feels very good. The
latest myocardial biopsy proved neither rejection nor presence
of the amyloid. Systolic function of the graft is normal with
LVEF 60% with a mild diastolic dysfunction and with right
ventricle dilatation, which is a common finding in patients after
heart transplantation, and is long-term stationary.3. Discussion
Amyloidosis is a rare but serious illness. It is caused by the
extracellular deposition of proteins, called amyloid, in var-
ious tissues of the body. The most affected organs are the
kidneys, heart and liver [1,2]. According to the type of
precursor protein, amyloidosis is divided into 5 basic types.
The most frequent type, 85% of all amyloidosis, is primary
light chain (AL) amyloidosis [3]. Cardiac amyloidosis is mainly
detectable in patients with AL amyloidosis. The basic non-
invasive examination for diagnosis of myocardial involve-
ment is echocardiography. In the early stages of amyloidosis,
there is a concentric hypertrophy of the left ventricle with an
impaired diastolic function. In advanced stages, the systolic
function of the left ventricle is also impaired and there is a
typical image of restrictive cardiomyopathy, with dilatation of
both atria and the right ventricle. This typical echocardio-
graphic image was present in our patient. It is necessary to
Table 1 – Serum levels of free light-chain lambda, kappa and their ratio.
Date of blood
collection
FLC kappa
(mg/l)
FLC lambda
(mg/l)
Kappa/Lambda
ratio
17.4.2010 15.1 223 0.07
27.4.2010 14.7 335 0.04
28.4.2011 17.2 46.1 0.37
7.6.2011 18.9 53.6 0.35
13.7.2011 11.8 75.7 0.16
18.8.2011 17.8 76.4 0.23
29.9.2011 18.1 88.9 0.2
29.11.2011 14.4 105 0.14
22.12.2011 26 123 0.21
6.3.2012 24.3 50 0.49
20.3.2012 29.4 37.5 0.78
17.4.2012 23.2 56.4 0.41
15.5.2012 17.5 28.3 0.61
12.6.2012 19.2 22.3 0.86
10.7.2012 17.2 15.6 1.1
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Graph 1 – Serum levels of FLC (free light chain) lambda and
kappa in connection with HDM-ASCT (high dose
melphalan—autologous stem cell transplantation) and
adjuvant chemotherapy.
Fig. 5 – (A, B) Histological sample of explanted heart—green birefrigence of interstitial deposits of amyloid (polarization
microscopy). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this
article.)
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 4 6 8 – e 4 7 3 e471evaluate left ventricle diastolic function for early diagnosis
and early therapy initiation. Amyloid is stored in the sub-
endocardial layer of the myocardium, where longitudinal
fibers are predominantly represented, causing longitudinal
contraction impairment. A reduction of longitudinal contrac-
tility, which can be detected by tissue Doppler imaging (TDI),
precedes a decrease of LVEF. TDI is used in connection with
the evaluation of pulse Doppler records of transmitral flow to
detect left ventricle diastolic dysfunction, which is a common
finding in cardiac amyloidosis [4]. Electrocardiogram shows
low voltage QRS complex, which is in apparent contrast to
myocardial wall hypertrophy, which was again seen in our
presented patient. Magnetic resonance has become a very
important diagnostic method in recent years, but in our
described case report it was not performed, because the
diagnosis of cardiac amyloidosis was determined histologi-
cally from previously performed endomyocardial biopsy.
For this reason, we did not consider necessary to perform
this examination. Magnetic resonance with late gadolinium
enhancement is used for the detection of cardiac involve-
ment. We can see typical view of contrast storing in sub-
endocardial layer of myocardium. Sensitivity and specificity
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 4 6 8 – e 4 7 3e472are approximately 85-90% and positive predictive value is 90%
[5]. In addition to imaging methods we use laboratory
methods, particularly immunofixation, to determine levels
of immunoglobulin light chains in serum and urine (sensi-
tivity of this method is 69% from serum and 83% from urine;
together 90%). For specific identification, we use a quantita-
tive determination of the serum free light chain (FLC) kappa
and lambda (immunoassay), which is a method approxi-
mately 100 times more sensitive than immunofixation (sen-
sitivity 95%). In addition to diagnostic and prognostic
significance, determining the FLC levels helps evaluate treat-
ment response [6,7], which was documented in our case.
Based on the dynamics of FLC levels after ASCT, administra-
tion of adjuvant chemotherapy was indicated. The combina-
tion of these methods increases sensitivity of diagnosis to
99%. The gold standard for diagnosis remains the identifica-
tion of amyloid from endomyocardial biopsy, which has
almost 100% sensitivity for the collection of at least 4 samples
[8]. After diagnosis, further therapy is managed interdiscipli-
narily in cooperation with a hemato-oncological center. The
prognosis of patients with manifest heart failure is very poor.
The median survival rate without treatment is about 6
months [9]. Early diagnosis is an important prognostic indi-
cator, because patients without impaired left ventricle sys-
tolic function can be treated with myeloablative therapy. If
myeloablative therapy cannot be administered, it is possible
to give a non-myeloablative treatment regimen consisting
mostly of administration of melphalan with prednisone or
according to more recent works, with dexamethasone. This
therapeutic regimen prolongs the median survival rate to
more than a year, but usually is not a curative treatment. The
results of Jaccard’s work with melphalan and dexamethasone
indicate that this combination could be more hopeful than
ASCT [10]. A myeloablative scheme consisting of high dose
melphalan followed by ASCT appears to be a suitable treat-
ment regimen. According to the work of Maurer et al., the
one-year survival rate for patients who underwent a heart
transplantation with subsequent ASCT was significantly
higher than for patients without heart transplantation (80%
vs. 17%, p¼0,0005) [11]. It is necessary to examine the
patients very carefully before an electing heart transplanta-
tion and to exclude multiorgan involvement which is a
contraindication for heart transplantation. Patients after
heart transplantation for cardiac amyloidosis with subse-
quent ASCT have procentually three-year survival rate 83%,
which is similar to patients transplanted for other diagnosis
[12]. Long-term survival is already lower in patients trans-
planted for AL amyloidosis without subsequent hematologi-
cal treatment, when a four-year survival rate is about 40%,
which is caused by amyloid recurrence in the transplanted
heart and progression multiorgan failure [13]. Periprocedural
mortality of ASCT is higher in patients with amyloidosis than
in patients treated for another diagnosis, especially in indi-
viduals with a pre-existing heart disability. Patients with
significant left ventricle systolic dysfunction (ejection frac-
tion below 40%) or with the symptoms associated with NYHA
class III and IV are contraindicated for this procedure for
these reasons [2,8]. This situation occurred in our patient. We
decided, after consultation with a hemato-oncologist, on this
unique solution: heart transplantation with subsequentASCT. This therapeutic method had not previously been used
in the Czech Republic; even in the literature we found only
the previously mentioned descriptions of small patient
groups or case reports [11–14]. Based on these articles and
our own experience, this is a viable therapeutic procedure
for selected patients with AL amyloidosis and advanced
heart failure.4. Conclusion
This case shows the possibility of a significant improvement
of short-term prognosis of patients with advanced heart
failure due to the primary AL amyloidosis treated with heart
transplantation and subsequent ASCT. Such a complicated
medical procedure requires the cooperation of an experi-
enced transplant center for the heart and stem cell trans-
plants. This cooperation should be initiated at the time of
early decisions about treatment possibilities, advance over
the period of preparation, stem cell collection, and trans-
plantation, when it is necessary to modify the basal immu-
nosuppressive therapy, and continue for the whole life of the
patient.Acknowledgments
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